Skip to main content

Day: July 1, 2021

Volatus Aerospace Corp.and Partner Jet Corp. Announce Closing of Upsized and Oversubscribed Subscription Receipt Private Placement for Gross Proceeds of Approximately C$9.2 million and Execution of Definitive Agreement for Reverse Takeover

Written by Customer Service on . Posted in Mergers And Acquisitions.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW. TORONTO, June 30, 2021 (GLOBE NEWSWIRE) — Volatus Aerospace Corp. (“Volatus“) and Partner Jet Corp. (“Partner Jet”) (TSXV:PJT) are pleased to announce that Volatus has closed its previously announced private placement (the “Offering”) of subscription receipts (each, a “Subscription Receipt” and collectively, the “Subscription Receipts“). The Offering was oversubscribed and upsized from C$7.5 million to approximately C$9.2 million due to demand. Upon closing of the Offering, 14,051,932 Subscription Receipts were issued at a price of $0.65 per Subscription Receipt (the “Issue Price”) for aggregate gross proceeds...

Continue reading

Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Written by Customer Service on . Posted in Public Companies.

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids. Excessive use of opioids in this patient population continues to be a major focus for US healthcare policymakers, regulatory authorities, patients and physicians, with more than 50% of US opioid prescriptions being for the treatment of CLBP.1,6,7 Mesoblast has filed a request and expects to hold a Type C meeting with the US Food & Drug Administration (FDA) during the current quarter to discuss the pathway to US regulatory approval for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.